Natera (NASDAQ:NTRA) CFO Sells $184,000.30 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Brophy sold 470 shares of the stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $391.49, for a total transaction of $184,000.30. Following the completion of the transaction, the chief financial officer directly owned 45,779 shares of the company’s stock, valued at approximately $17,922,020.71. The trade was a 1.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, November 2nd, Michael Brophy sold 325 shares of Natera stock. The shares were sold at an average price of $399.99, for a total transaction of $129,996.75.
• On Wednesday, October 28th, Michael Brophy sold 1,178 shares of Natera stock. The shares were sold at an average price of $426.46, for a total transaction of $502,369.88.
• On Friday, October 30th, Michael Brophy sold 1,906 shares of Natera stock. The stock was sold at an average price of $425.55, for a total transaction of $811,098.30.
• On Wednesday, October 28th, Michael Brophy sold 1,198 shares of Natera stock. The shares were sold at an average price of $426.34, for a total value of $510,755.32.
• On Tuesday, October 27th, Michael Brophy sold 781 shares of Natera stock. The stock was sold at an average price of $406.00, for a total value of $317,086.00.

Natera Trading Down 14.6%

NASDAQ NTRA opened at $310.67 on Friday. Natera, Inc. has a twelve month low of $181.00 and a twelve month high of $437.41. The firm has a 50-day simple moving average of $380.25 and a 200 day simple moving average of $269.68.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, November 5th. The medical research company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.14). Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $793.98 million for the quarter, compared to analyst estimates of $707.54 million. During the same period last year, the business earned ($0.64) EPS. The company’s revenue was up 34.1% compared to the same quarter last year. As a group, sell-side analysts expect that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

Institutional Trading of Natera

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Diversified Trust Co lifted its position in shares of Natera by 81.4% during the 3rd quarter. Diversified Trust Co now owns 2,353 shares of the medical research company’s stock worth $973,000 after buying an additional 1,056 shares during the last quarter. Aberdeen Group plc raised its holdings in Natera by 26,462.7% during the third quarter. Aberdeen Group plc now owns 1,398,794 shares of the medical research company’s stock valued at $578,136,000 after buying an additional 1,393,528 shares in the last quarter. HBE Wealth Management LLC acquired a new stake in shares of Natera during the 3rd quarter worth about $208,000. Allworth Financial LP increased its position in shares of Natera by 2.5% in the 3rd quarter. Allworth Financial LP now owns 3,975 shares of the medical research company’s stock valued at $1,643,000 after buying an additional 97 shares in the last quarter. Finally, Private Advisory Group LLC bought a new position in Natera during the third quarter worth $3,521,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Third-quarter revenue rose 34.1% year over year to $794 million, beating analyst expectations. Natera also raised its fiscal 2026 sales outlook, supporting the growth outlook for its testing business. Natera Q3 results and outlook
• Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could broaden access to the cancer-monitoring test and support adoption. Medicare coverage for Signatera in HCC
• Neutral Sentiment: JPMorgan lowered its price target from $460 to $405 but maintained an Overweight rating, indicating continued confidence while marking down its valuation expectations. JPMorgan price-target update
• Negative Sentiment: CEO Steve Chapman is stepping down, creating uncertainty around leadership and the transition. The announcement weighed on sentiment despite the stronger revenue outlook. CEO transition and market reaction
• Negative Sentiment: The quarterly per-share loss was wider than analysts expected (about $0.42 versus a $0.28 consensus loss), despite revenue beating estimates. This earnings miss appears to have contributed to the selloff. Natera third-quarter financial results

Analyst Ratings Changes

A number of brokerages have weighed in on NTRA. Robert W. Baird set a $348.00 price target on shares of Natera in a report on Friday, August 7th. Piper Sandler reissued an “overweight” rating and set a $363.50 price objective on shares of Natera in a report on Friday. JPMorgan Chase & Co. decreased their target price on shares of Natera from $460.00 to $405.00 and set an “overweight” rating for the company in a research note on Friday. TD Cowen upped their price target on Natera from $340.00 to $480.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Finally, Leerink Partners set a $330.00 target price on Natera in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus price target of $391.69.

About Natera

Natera, Inc is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring.

In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.

The company also provides Prospera, a molecular test used to help assess organ transplant rejection.